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OBJECTIVE—Increased oxidative stress (OS) and impaired anti-OS defenses are important
in the development and persistence of insulin resistance (IR). Several anti-inﬂammatory and
cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1
(AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are sup-
pressed in diabetes. Because basal OS in type 2 diabetic patients is inﬂuenced by the consump-
tion of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and
SIRT1 are involved.
RESEARCH DESIGN AND METHODS—The study randomly assigned 36 subjects, 18
type 2 diabetic patients (age 61 6 4 years) and 18 healthy subjects (age 67 6 1.4 years), to a
standard diet (.20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (,10 AGE
Eq/day) for 4 months. Circulating metabolic and inﬂammatory markers were assessed. Expres-
sion and activities of AGER1 and SIRT1 were examined in patients’ peripheral blood mono-
nuclearcells(PMNC)andinAGE-stimulated,AGER1-transduced(AGER1
+),orAGER1-silenced
human monocyte-like THP-1 cells.
RESULTS—Insulin and homeostasis model assessment, leptin, tumor necrosis factor-a and
nuclear factor-kB p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted
type2diabeticpatients,whereasPMNCAGER1andSIRT1mRNA,andproteinlevelsnormalized
and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD
+ levels in
THP-1cells.TheseeffectswereinhibitedinAGER1
+butwereenhancedinAGER1-silencedcells.
CONCLUSIONS—Food-derived pro-oxidant AGEs may contribute to IR in clinical type 2
diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve
native defenses and insulin sensitivity by maintaining lower basal OS.
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I
nsulin action is regulated by multiple
factors, including SIRT1, a member of
the sirtuin (silent mating type infor-
mation regulation 2 homolog) 1 family of
NAD
+ deacetylases, which acts via signal-
ing mediators and transcription factors,
including nuclear factor-kB( N F - kB), fork-
headboxclassO,peroxisomeproliferator–
activatedreceptor-g,andadiponectin(1–3).
Because SIRT1 activity also modulates the
functionsofmonocytesandmacrophages,
native defenses may play a key role in
insulinresistance(IR), and type2diabetes
(3,4).SIRT1 activity isdecreased in diabe-
t e s( 4 , 5 ) ,a si sa d v a n c e dg l y c a t i o ne n d
product (AGE) receptor-1 (AGER1) (6).
Because AGEs are oxidants that are nor-
mally controlled by AGER1 (7–9), de-
creased AGER1 may result in increased
oxidative stress (OS) and inﬂammation
(6).Inaddition,exposuretoglycoxidants
when AGER1 levels are reduced may
have a negative effect on SIRT1, which
could contribute to IR.
The increasing prevalence of IR and
type 2 diabetes is directly related to the
Western lifestyle and diet (10). Excessive
intake of fats or carbohydrates is thought
to play a major role in the development of
IR (11,12), although a direct link has not
been established. A clear relationship has
been found between inﬂammation, OS,
and IR (13). Therefore, because AGEs in-
crease inﬂa m m a t i o na n dO Si nn o r m a l
subjects, as well as in diabetic patients,
they may also play a role in IR.
Glycoxidants are partially absorbed as
food-derivedAGEpeptidesandAGElipids
by mechanisms not fully elucidated (14).
Experiments in animals have shown a
strong link between high oral glycoxidant
intake, IR, type 2 diabetes, and diabetes
complications (15–18). Direct evidence
thatoralAGEspromoteOSandcausemet-
abolic changes was provided by studies of
mice that were pair fed a low-AGE diet or
the same diet supplemented with a well
deﬁned AGE (methylglyoxal [MG]-BSA)
(16).AnexcessofAGEsledtoOS,IR,and
renal/vascular disease, whereas restric-
tion of AGEs, without altering caloric or
nutrient intake, reduced OS and inﬂam-
mation,amelioratedIR,andextendedthe
life span in mice (16). Clinical studies in
healthy subjects, diabetic patients, and
individuals with chronic kidney disease
showed that AGE restriction substan-
tially reduced OS and inﬂammation
and improved native defenses, including
AGER1 (9,19).
In the current study, we investigated
the relationship between IR and dietary
AGEs in type 2 diabetic patients. We
report that AGE restriction lowers insulin
levels, markers of IR, and inﬂammation.
In addition, the suppressed expression
a n df u n c t i o no fA G E R 1a n dS I R T 1i n
diabetic peripheral blood mononuclear
cells (PMNCs) are nearly normalized by
AGE restriction, consistent with restora-
tion of host defenses.
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Pathophysiology/Complications
ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
Study design
The study enrolled 18 type 2 diabetic
patients (14 women, 4 men; average age,
61 6 4 years), without renal disease or
overt cardiovascular disease, and a usual
diet rich in AGE (dietary AGE intake
;.20 AGE equivalents [Eq]/day; Table 1).
All study subjects continued to receive
standard medical care: 20% were treated
only with diet, and 80% received oral anti-
diabetic medications, including 15 with
metformin and 1 each with pioglitazone,
glipizide, and glimepiride; 60% were re-
ceiving statins and ACE inhibitors or
angiotensin-receptor blockers, and 40%
were taking aspirin (81 mg daily).
They were randomly assigned to an
AGE-restricteddiet(n=12)ortheirusual
diet (n =6 )f o r4m o n t h s .T h eA G E -
restricted group received instructions on
how to modify cooking time and tempera-
ture but not the quantity or nutrient com-
positionoffood.Theywereadvisedtoboil,
poach, stew, or steam food and to avoid
frying, baking, or grilling, methods, which
limit dietary AGE intake by ;40–50%
(9,19,20). The control group comprised
18 age-matched (age 67 6 1.4 years),
healthy volunteers selected from a larger
wellcharacterizedcohortthatwasrandom-
ized to the same AGE-restricted diet for
4 months (9).
A dietitian monitored participants by
telephone 1–2 times per week and at
monthly clinic visits. The study diets
were designed to maintain daily require-
ments of calories and nutrients in both
arms but to restrict AGE intake only on
the AGE-restricted arm. Nutritional in-
take was closely monitored in both
groups.
The study and consent forms were
approved by the Mount Sinai School of
Medicine Institutional Review Board. All
participants provided informed consent.
Human subjects
Participants received a physical examina-
tion and provided a fasting blood sample
anda24-hurinecollectionatbaselineand
at 4 months. Routine blood and urine
tests were performed by the hospital
clinical laboratory.
Dietary intake
D a i l yd i e t a r yA G Ec o n t e n t ,f r o m3 - d a y
food records that emphasized cooking
methods, was estimated from a database
that listed AGE values of ;560 foods and
was expressed as AGE equivalents/day
(AGE Eq = 1,000 kilounits) (20). The
3-day food record is based on established
guidelines developed to allow estimation
of food and beverage consumption at
home and away from home. The dietitian
reviewed the record with the subject,
probing for details on portion sizes and
preparation methods, to ensure accuracy
and compliance. Nutrient calculations
were estimated by using the Food Pro-
cessor 10.1 nutrient software program
(ESHA Research, Salem, OR).
Assessment of AGEs, insulin, and
inﬂammation
Derivatives of N
´-carboxymethyl-lysine
(CML) and methylglyoxal (MG) in serum
were quantiﬁed by established enzyme-
linked immunosorbent assays (ELISAs)
using monoclonal antibodies (4G9 and
MG3D11) (9,21), validated against syn-
theticstandards,CML-BSA(23modiﬁed
lysines/mol) and MG-BSA (20 MG-
modiﬁed arginines/mol), based on high-
performance liquid chromatography and
gas chromatography-mass spectroscopy
(21). Insulin was measured by an ELISA
kit (ALPCO Diagnostics, Salem, NH). IR
was estimated by the homeostasis model
assessment(HOMA)indexas[FI3(fasting
glucose/22.5)], where FI is insulin in
microunits per milliliterand fasting glu-
cose is in millimoles per liter(9). ELISA
kitswereusedformeasuringplasmaleptin,
adiponectin (Millipore, Billerica, MA), and
PMNC tumor necrosis factor (TNF)-a
(BiosourceInternational,Camarillo,CA).
PMNCs
PMNCs were separated from fasting,
EDTA-anticoagulated blood by Ficoll-
Hypaque Plus gradient (American Bio-
sciences, Uppsala, Sweden) and used to
isolate mRNA and protein (9,19). Total
RNA was extracted by TRIzol (Invitrogen-
MolecularProbes,Inc.,Eugene,OR).The
extracted RNA had an optical density of
280/260 ratio of between 1.8 and 2.0.
Total RNA was reverse-transcribed using
Superscript III RT (Invitrogen, Carlsbad,
CA).
Table 1—Baseline clinical characteristics and other parameters in the study population
Variables
Diabetes Healthy
n =1 8 n =1 8 P
Age (years) 61 6 46 7 6 10 . 1 6 5
Sex NS
Male 4 4
Female 14 14
BMI (kg/m
2) 32.3 6 1.6 27.3 6 1.4 0.024
Waist circumference (cm) 108 6 49 3 6 40 . 0 1 3
Fasting blood glucose (mg/dL) 120 6 14 84 6 30 . 0 1 6
Insulin (mU/mL) 17 6 18 6 10 . 0 0 1
HOMA-IR 5.00 6 0.51 1.66 6 0.24 0.001
Triglycerides (mg/dL) 100 6 11 80 6 90 . 1 5 7
HDL cholesterol (mg/dL) 51 6 37 2 6 40 . 0 0 2
Serum CML (units/mL) 17.4 6 1.1 12 6 0.5 0.001
Serum MG (nmol/mL) 2.6 6 0.10 1.1 6 0.06 0.001
Intracellular CML (units/mg) 7.9 6 1.8 5.7 6 2.3 0.005
Intracellular MG (nmol/mg) 0.87 6 0.28 0.70 6 0.38 0.148
8-Isoprostane (pg/mL) 234 6 14 130 6 11 0.033
Plasma leptin (ng/mL) 36 6 3.6 15 6 2.7 0.001
Plasma adiponectin (mg/mL) 7 6 0.5 16 6 2.6 0.004
AGER1 (mRNA) 133 6 11 225 6 28 0.011
RAGE (mRNA) 532 6 77 464 6 67 0.511
SIRT1 (mRNA) 282 6 27 378 6 27 0.029
p66
shc (mRNA) 113 6 20 66 6 60 . 0 4 7
NOX p47
phox (mRNA) 220 6 24 125 6 19 0.026
TNF-a (ng/mg protein in PMNCs) 18.5 6 0.8 10 6 0.5 0.001
Caloric intake (kcal/day) 2,329 6 248 2,120 6 215 0.934
AGE intake (AGE Eq/day) 23 6 31 8 6 1.3 0.135
Creatinine clearance* 92 6 79 8 6 40 . 4 3 1
Continuous data are expressed as mean 6 SEM and categoric data as n. P values reﬂect differences between
means of diabetic and healthy subjects at baseline. NS, not signiﬁcant. *Calculated as mL/min/1.73 m
2.
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transfection
THP-1 human monocytes (1 3 10
6/mL)
(AmericanTypeCultureCollection,Manas-
sas, VA) were cultured in RPMI-1640
medium (1% FBS). THP-1 cells were trans-
fected with AGER1, SIRT1 or short-hairpin
RNA AGER1 (0.5 mgo fD N A )b yu s i n gt h e
human monocyte cell line nucleofector kit
(Amaxa Biosystems, Cologne, Germany).
Quiescent cells were exposed to CML-BSA,
MG-BSA, or BSA, with or without the
following inhibitors: sirtinol (10 mmol/L;
Calbiochem,LaJolla, CA);N-acetylcysteine
( [ N A C ] ,5m m o l / L ;S i g m a - A l d r i c h ,S t .
Louis, MO); apocynin (300 mmol/L;
Sigma-Aldrich); and Mn superoxide dis-
mutase(1,000units/mL;Sigma-Aldrich).
AGEs used for in vitro studies
Synthetic preparations of CML-BSA (23
CML-Lys/mol),MG-BSA(22MG-Arg/mol)
(21), and BSA (Fraction V; Sigma-Aldrich)
were rendered LPS-negative before use by
a Detoxigel column (Pierce, Rockford, IL),
based on Limulus assay (BioWhittaker,
Walkerville, MD).
Quantitative RT-PCR assay
AGER1, receptor for AGE (RAGE), the
66-kDa protein from the src homology
and collagen homology domain (p66
shc),
SIRT1, and NADPH oxidase 1 (NOX)
p47
phox mRNA levels were assessed by
quantitative SYBR Green real-time PCR
(9). Primer sequences were as follows:
AGER1, forward primer 59-CTGGGGC
TCTTCATCTTCAG-39, reverse primer
59-GTTGCATCTCCCACAGAGGT-39;
RAGE, forward primer 59-AGGAGCGTG
CAGAACTGAAT-39, reverse primer
59-TTGGCAAGGTGGGGTTATAC-39;
p66
shc,forwardprimer59-AGGAAGGGC
AGCTGATGAT-39, reverse primer
59-GCGTGGGCTTATTGACAAAG-39;
NOXp47
phox,forwardprimer59-ACAGCG
TCCGTTTTCTGC-39,reverseprimer59-
AGCGGTTCAGGATGAGGTC-39;a n d
SIRT1, forward primer 59-CGGAAACAAT
ACCTCCACCT-39, reverse primer 59-
CACCCCAGCTCCAGTTAGAA-39.
Emission from each sample was re-
corded during thermal cycling, and the
raw ﬂuorescence data were processed
using Sequence Detection System software
(Applied Biosystems, Carlsbad, CA) to
produce threshold cycle (Ct) values for
each sample. b-Actin and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)
housekeeping genes were used for internal
normalization.Thetranscriptcopynumber
of target genes was determined based on
their Ct values (9).
Western analysis and
immunoprecipitation
Cell proteins were separated on 8% SDS-
PAGE gels, transferred onto nitrocellulose
(NT)membranesforprobingwithprimary
and secondary antibodies, and visualized
by an enhanced chemiluminescence sys-
tem (Roche, Mannheim, Germany) (7,18).
For immunoprecipitation, the lysate (300
mgprotein)wasincubatedovernightat4°C
with the appropriate antibody, followed
by 60 mL protein A/G plus agarose beads
(Santa Cruz Biotechnology, Santa Cruz,
CA) for 2 h. Bound immune complexes
in radioimmunoprecipitation assay lysis
buffer were used for immunoblotting after
SDS-PAGE and NT transfer (9).
NF-kB p65 acetylation
Cells (PMNCs, THP-1) were disrupted in
lysis buffer (Sigma-Aldrich, C2978), and
100 mg protein was immunoprecipitated
with anti-NF-kB-p65 (Santa Cruz Biotech-
nology) at 4°C overnight. A total of 60 mL
protein agarose (A/G) beads were added,
and immunoprecipitates were immuno-
blotted for acetyl-lysine residues (4). For
densitometric analysis, acetyl-p65 was nor-
malized for total p65.
NAD/NADH determination
NAD and NADH were measured using an
Amplite Fluorimetric NAD/NADH assay
kit (AAT Bioquest, Inc., Sunnyvale, CA).
Cells (wild-type or AGER1-transfected)
werelysedafterstimulationwithMG-BSA
(60 mg / m L )f o r7 2hi nt h ep r e s e n c eo r
absence of antioxidants NAC (5 mmol/L)
a n da p o c y n i n( 3 0 0mmol/L).
Statistical analysis
Data in the tables and ﬁgures are pre-
sentedasmeans6SEM.TheKolmogorov-
Smirnov goodness-of-ﬁt test was used to
test for normal distribution. Variables not
normally distributed were logarithmically
converted for analyses. Differences of means
between groups were analyzed by the Stu-
dent t test or ANOVA, followed by the
Bonferroni correction for multiple compar-
isons, depending on the number of groups.
Correlation analyses were also examined
by the Pearson correlation coefﬁcient.
Signiﬁcance of changes during the
interventional study was assessed by com-
paring1)changeofmeansbetweenbaseline
and end of study within each group by
paired t test, 2) percentage of change from
baselinetotheendofthestudybetweenthe
AGE-restricted and the regular AGE diet
groups by the Mann-Whitney test, and 3)
differences between the means of both
groups at the end of the study by unpaired
t test. Signiﬁcant differences were deﬁned
asavalueofP,0.05andarebasedontwo-
sided tests. Data analysis was performed in
consultation with a statistician, using SPSS
17.0 software (SPSS, Chicago, IL).
RESULTS
Baseline data
The type 2 diabetic patients, age- and sex-
matchedwithnondiabeticcontrolsubjects,
had similar levels of creatinine clearance
(Table1).Comparedwithhealthysubjects,
type 2 diabetic participants had signiﬁ-
cantlyhigherfastingbloodglucose,plasma
insulin, HOMA, BMI, waist circumference,
serum CML (sCML), serum MG (sMG),
and leptin but lower adiponectin. They
also had signiﬁcantly higher levels of se-
rum AGEs and plasma 8-isoprostanes
(Table 1).
AGER1 and SIRT1 mRNA levels in
PMNCs from diabetic subjects were sig-
niﬁcantly lower than in healthy subjects
(Table1).Concentrationsofpro-OSp66
shc
and NAPDH oxidase p47
phox mRNA and
TNF-a protein, a proinﬂammatory cyto-
kine, were elevated, as were intracellular
AGEs (iCML; Table 1). These data were
consistent with high baseline OS.
Intervention data
Serum and plasma changes after AGE
restriction. AGE restriction (by 50%),
without altering nutrient intake, led to
markedly lower levels of sCML and sMG,
as well as 8-isoprostanes in type 2 diabetic
subjects (Table 2, Fig. 1A). Plasma insulin,
HOMA, and leptin levels were also de-
creased by ;30% below baseline by AGE
restriction (Table 2, Fig. 1A). However,
adiponectin levels were doubled after AGE
restriction, resulting in a markedly lower
leptin/adiponectin ratio (Fig. 1A,i n s e t ) .
Type 2 diabetic subjects on the regular
diet showed no signiﬁcant changes, except
for higher sMG, iCML, leptin, and TNF-a
values (Table 2), consistent with sustained
high AGE intake and AGE accumulation.
Neither the diabetic patients nor the
healthy subjects had changes in weight
(96.0 6 7t o9 7 . 36 8 kg vs. 83.6 6 6t o
82.0 6 6 kg, respectively), BMI, plasma
lipids, blood glucose, or HbA1c after
4 months. Healthy subjects on the AGE-
restricted diet had no signiﬁcant changes,
withtheexceptionofdecreasedsAGEsand
8-isoprostanes (Table 2).
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cohort. ThesuppressedbasalmRNAlevels
of AGER1 and SIRT1 in type 2 diabetic
patients were increased by ;50%, almost
to the normal range in the AGE-restricted
cohort (Fig. 1A; Table 2) (9). The changes in
mRNAofAGER1andSIRT1correlatedwith
changes in protein expression (Fig. 1B). In-
tracellular AGE levels in the AGE-restricted
group were decreased, iMG (P =0 . 0 0 2 )a n d
iCML (P = 0.148; Table 2), consistent with
increased AGER1 expression.
There was also a reduction in NF-kB
acetyl-p65 (Fig. 1C), associated with
trends of lower RAGE mRNA and TNF-a
protein in PMNCs from AGE-restricted
type 2 diabetic subjects (Table 2). In con-
trast, in diabetic subjects who ate the
regular diet, PMNC SIRT1 remained de-
pressed (Fig. 1B and C; Table 2), whereas
acetyl-p65, TNF-a, and RAGE remained
elevated in diabetic subjects, consistent
with higher circulating oxidants, AGEs,
and 8-isoprostane (Table 2).
In vitro effects of AGEs on THP-1
AGER1 and SIRT1 expression
and function
Because SIRT1 (4,23) and AGER1 (6–8)
are suppressed in patients with diabetes
(high OS), monocyte-like THP-1 cells
were used as inﬂammatory cells to inves-
tigatetheobservationsinPMNCs.AGER1
and SIRT1 protein expression levels were
coordinately suppressed in THP-1 cells
after chronic exposure to CML or MG
(but not unmodiﬁed BSA; Fig. 2A). In
addition, AGER1 and SIRT1 expression
was enhanced in AGER1-overexpressing
(AGER1
+) cells treated with MG but re-
duced in AGER1-silenced THP-1 cells
(Fig. 2B and C). After a transient induc-
tion,amarkedtime–dependentreduction
of the NAD
+/NADH ratio was noted in
association with suppressed SIRT1 levels,
Table 2—Intervention: Changes in biochemical, metabolic, and cellular parameters in diabetic patients and in healthy control
subjects after AGE restriction
Variable
Diabetic patients
P‡ P§
AGE-restricted diet (n = 12) Regular AGE diet (n =6 )
Baseline End P* Baseline End P†
sCML (units/mL) 17.1 6 1.3 11.6 6 1.1 0.005 17.8 6 2 24.2 6 4 0.199 0.001 0.012
sMG (nmol/mL) 2.6 6 0.2 1.8 6 0.2 0.005 2.6 6 0.2 3.5 6 0.3 0.039 0.001 0.009
iCML (units/mg) 8.1 6 0.9 6.5 6 0.5 0.148 7.6 6 0.3 10.5 6 0.9 0.023 0.007 0.001
iMG (nmol/mg) 0.97 6 0.10 0.52 6 0.05 0.002 0.76 6 0.12 1.08 6 0.15 0.117 0.003 0.004
AGER1 (mRNA) 125 6 15 193 6 20 0.018 144 6 16 97 6 16 0.069 0.003 0.003
RAGE (mRNA) 530 6 111 270 6 70 0.064 467 6 110 690 6 109 0.179 0.002 0.018
SIRT-1 (mRNA) 268 6 24 409 6 53 0.040 300 6 53 205 6 38 0.176 0.007 0.010
TNF-a (ng/mg) 18 6 11 4 . 4 6 20 . 0 7 8 2 0 6 22 6 6 2 0.030 0.002 0.029
Insulin (mU/mL) 19 6 11 2 6 1.2 0.001 14 6 1.7 19 6 2 0.069 0.001 0.021
FBG (mg/dL) 114 6 71 1 1 6 9 0.801 131 6 37 129 6 26 0.970 0.205 0.688
HOMA 5.3 6 0.4 3.4 6 0.6 0.023 4.5 6 1.2 6.2 6 0.5 0.393 0.001 0.160
HbA1c (%) 6.4 6 0.2 6.6 6 0.4 0.347 6.7 6 0.5 6.5 6 0.4 0.770 0.089 0.656
8-Isoprostane (pg/mL) 233 6 17 141 6 18 0.006 236 6 25 313 6 77 0.289 0.053 0.039
Leptin (ng/mL) 38 6 0.6 26 6 2.6 0.074 34 6 55 2 6 5 0.023 0.003 0.044
Adiponectin (mg/mL) 5.6 6 0.6 10.4 6 0.9 0.002 7.7 6 0.7 4.6 6 0.5 0.006 0.003 0.001
Healthy control subjects
AGE-restricted diet (n = 9) Regular AGE diet (n =9 )
P‡ P§ Baseline End P* Baseline End P†
sCML (units/mL) 12.4 6 0.5 9.3 6 1.0 0.016 11.7 6 0.8 14.0 6 1 0.168 0.002 0.012
sMG (nmol/mL) 1.1 6 0.1 0.9 6 0.1 0.049 1.0 6 0.1 1.2 6 0.1 0.330 0.026 0.052
iCML (units/mg) 5.5 6 1.0 7.0 6 1.2 0.366 5.9 6 0.6 5.3 6 0.7 0.502 0.186 0.256
iMG (nmol/mg) 0.63 6 0.12 0.76 6 0.18 0.538 0.75 6 0.12 0.63 6 0.12 0.514 0.137 0.552
AGER1 (mRNA) 226 6 46 207 6 45 0.767 224 6 36 278 6 43 0.345 0.137 0.270
RAGE (mRNA) 534 6 133 372 6 81 0.323 413 6 65 628 6 136 0.174 0.001 0.125
SIRT1 (mRNA) 383 6 34 288 6 100 0.388 368 6 42 420 6 169 0.783 0.686 0.634
TNF-a (ng/mg) 10.0 6 1.3 8.4 6 0.7 0.293 8.6 6 0.6 11.8 6 1 0.015 0.002 0.013
Insulin (mU/mL) 10.6 6 11 1 . 3 6 2.4 0.802 5.9 6 1.1 7.4 6 1.4 0.437 0.117 0.198
FBG (mg/dL) 86 6 38 8 6 60 . 7 1 0 8 3 6 48 0 6 4 0.509 0.785 0.259
HOMA 2.2 6 0.3 2.5 6 0.6 0.621 1.3 6 0.3 1.5 6 0.3 0.755 0.409 0.122
8-Isoprostane (pg/mL) 135 6 10 90 6 9 0.006 125 6 18 165 6 23 0.198 0.002 0.014
Leptin (ng/mL) 16 6 41 3 6 40 . 6 7 5 1 4 6 41 7 6 6 0.673 0.386 0.634
Adiponectin (mg/mL) 16 6 41 5 . 6 6 40 . 8 8 2 1 6 6 41 8 6 3 0.698 0.102 0.683
Data are presented as mean 6 SEM. FBG, fasting blood glucose. *Statistical signiﬁcance between baseline and end of study means in the AGE-restricted diet group.
†Statistical signiﬁcance between baseline and end of study means in the regular AGE diet group. ‡Statistical signiﬁcance in percentage change between baseline and
end of study between the AGE-restricted diet and the regular diet groups. §Statistical signiﬁcance between the means of both groups at the end of the study.
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dants (NAC, apocynin; Fig. 2D)a n db y
AGER1 overexpression (AGER1
+;F i g .2 E).
In addition, the AGE-induced NF-kBp 6 5
hyperacetylation seen in wild-type cells
wasblockedinAGER1
+cells(Fig.2F),con-
sistent with preserved SIRT1 function
when AGER1 is intact. These data were in
line with the PMNC ﬁndings from type 2
diabetic patients.
CONCLUSIONS—IR remains an un-
resolved scientiﬁc and therapeutic prob-
lem. Increased OS and impaired anti-OS
defenses are important factors in the de-
velopment and persistence of IR (2–4).
ThecurrentstudyshowsthatAGErestric-
tion can improve IR in type 2 diabetes.
Plasma insulin, markers of inﬂammation,
and OS were substantially improved in
diabetic subjects by an intervention that
restricts oxidant (AGE) load without al-
tering energy balance. These ﬁndings are
consistentwithevidenceshowingthatex-
cessive food AGEs promote inﬂammation
and OS in humans (9,19) and IR in mice
(15,16). That plasma insulin was nearly
normalized after the AGE restriction in-
dicates that tissue glucose uptake was
improved. Therefore, a reduced demand
onb-cellsforinsulinrelease appearstobe
directly related to the AGE restriction.
While the ﬁndings must be conﬁrmed in
larger cohorts, AGE restriction may have
therapeutic advantages in IR.
Although endogenous glucose or lip-
ids contribute to elevated AGEs (22), ex-
ogenouslyAGE-modiﬁednutrientsare an
i m p o r t a n ts o u r c ei nb o t hh u m a ns u b j e c t s
and animals (9,14,16,19,20). The signiﬁ-
cant reduction in serum AGEs and lipid
peroxides (8-isoprostanes) after AGE re-
strictioninthe current study conﬁrmsthe
hypothesis that elevated AGEs in type 2
diabetes result from increased dietary
AGE intake, independently from glyce-
mic control (19).
AGE restriction normalized AGER1,
SIRT1, and SIRT1-dependent NF-kBp 6 5
deacetylation levels, and there was a con-
comitant attenuation of proinﬂammatory
mediators (i.e., RAGE and TNF-a)( 9 ) .
The decreased basal AGER1 and SIRT1
(mRNA and protein) levels in type 2 di-
abetic PMNCs suggests a link between
these two mechanisms. Since plasma insu-
lin and leptin levelsfell,whereasadiponec-
tin levels increased with AGE restriction,
thechangesinAGER1expression reﬂected
adjustments in both the inﬂammatory and
the metabolic states, effects previously at-
tributed to SIRT1 (2–4,23). Thus, high
AGE and low AGER1 levels in type 2 di-
abetes may partly account for the persis-
tence of IR in these patients.
Given that downregulation of AGER1
(7–9) and SIRT1 is linked to high OS con-
ditions (4,5), the current ﬁndings also in-
dicate that normal SIRT1 function may
depend on the ability of intact AGER1 to
control AGEs and OS. Thus, the loss of
AGER1 function may be one mechanism
leading to SIRT1 downregulation in type
2 diabetes. This postulate is supported in
thecurrentstudybythehighbasallevelsof
intracellularAGEsandlowAGER1levelsin
t y p e2d i a b e t i cP M N C .T h ef a c tt h a tt h e s e
levels are nearly normalized after AGE re-
striction lends further support to this hy-
pothesis. These data also suggest that low
steady-state levels of intracellular AGEs
may be crucial for maintaining AGER1 in-
tact (7–9,16,24).
BecausethiswastheﬁrsttimethatAGEs
and AGER1 were linked to the deacety-
lases and to SIRT1, we probed these rela-
tionships in inﬂammatory monocyte–like
Figure 1—A: AGE restriction reduces IR and improves inﬂammation in type 2 diabetic patients. Changes after AGE restriction (34m o n t h s )i n
circulatingfactors(byELISAs),plasmainsulin,andHOMA,leptin,adiponectin,serumCML,MG,orinPMNCs,andAGER1,SIRT1,RAGEmRNA
(byRT-PCR),areshownaspercentage(mean6SEM)aboveorbelowthebaseline.*P,0.050.Inset:Leptin(Lep)/adiponectin(Adipo)ratiobefore
andaftertreatmentisshownrelativetonormalcontrolsubjects(NL,atbaseline,openbars).B:AGErestrictionenhancesSIRT1andAGER1protein
expressioninPMNCs of type2diabeticpatients.PMNCsobtainedat entry(1)and atthe endof the study(2)areshown forsubjects exposedtoAGE
restriction (AGE-Restr) vs. regular diet (Reg). SIRT1 and AGER1 protein levels were assessed by Western blotting (upper panels), followed by
densitometric analysis (lowerpanels).C: AGE restriction enhances SIRT1 deacetylation of NF-kB p65. Levels of NF-kBp65acetylationareshown
at entry (1) and at the end of study (2) after immunoprecipitation (IP) and immunoblotting (IB) against acetyl-lysine residues. Data are shown as
the percentage (mean 6 SEM) change from entry (1). P values are as indicated.
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AGEs, AGER1 and SIRT1 were both sup-
pressed in these cells or became unrespon-
sive. AGEs acted via an OS-dependent
decrease in NAD
+, explaining the eventual
downregulationofSIRT1,andconsequently,
thehyperacetylationofNF-kBp65observed
in diabetic PMNCs (2,4). Since the AGE-
induced effects on SIRT1 and NF-kBw e r e
blocked in THP-1 cells by genetic modula-
tion of AGER1 expression, AGER1 is likely
to be involved in the regulation of inﬂam-
matoryresponsescontrolledbySIRT1.The
data also suggest that controlling the pro-
oxidant effects of AGEs could help preserve
normal AGER1 and SIRT1 functions.
From a clinical perspective, AGE re-
striction markedly increased adiponectin
levels and reduced the initially high leptin/
adiponectinratio,amarkerofIR,indicating
that AGEs also affect insulin-sensitive tis-
sues (2–5). Adiponectin improves insulin
sensitivity and is controlled by SIRT1 (25);
therefore, the doubling in adiponectin
levels after AGE-restriction provides an-
other insight into the improved metabolic
state in type 2 diabetic patients.
Thesedatashowthatchronicexposure
to excessive exogenous (food) oxidants
fosters an impairment in both native anti-
oxidant defenses as well as insulin action
andthatreducingoralAGEscanameliorate
these defects. This approach does not
restrict energy or caloric intake. Since the
effectsofAGErestrictionwereadditiveto
standard medical therapy, the intervention
could be a valuable addition to the current
managementofpatientswithtype2diabetes.
Larger trials are warranted to validate the
ﬁndingsand establish thelong-term effects
of this intervention on diabetes.
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